BioCentury | Jul 25, 2016
Company News

Transition Therapeutics, Opko deal

...of Opko. Transition did not respond to inquiries. Transition’s pipeline comprises ELND005 , TT401 and TT701...
...Indianapolis, Ind.) after the pharma elected not to advance the compound into Phase III trials. TT701...
BioCentury | Dec 14, 2015
Company News

Transition Therapeutics, Brigham and Women’s Hospital deal

...Transition partnered with the hospital to evaluate TT701 in a Phase II trial to treat androgen...
BioCentury | May 18, 2015
Company News

Eli Lilly, Transition Therapeutics deal

...Lilly granted Transition’s Transition Therapeutics Ireland Ltd. subsidiary exclusive, worldwide rights to develop and commercialize TT701...
Items per page:
1 - 3 of 3